Target Name: LOC100653061
NCBI ID: G100653061
Review Report on LOC100653061 Target / Biomarker Content of Review Report on LOC100653061 Target / Biomarker
LOC100653061
Other Name(s): Beta-glucuronidase-like protein SMA4-like, transcript variant 1 | Putative beta-glucuronidase-like protein SMA3 | GUSP1_HUMAN | LOC100653061 variant 1 | beta-glucuronidase-like protein SMA4-like | SMA3 | Putative inactive beta-glucuronidase-like protein SMA3 | Beta-glucuronidase-like protein SMA4-like (isoform 1)

LOC100653061: A Drug Target / Disease Biomarker

LOC100653061 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the superfamily of leucine-rich repeat (LRR) proteins, which are characterized by the presence of a series of leucine-rich repeats in their amino-terminal region. LRR proteins are known for their ability to form complex conformations that can interact with a wide range of ligands, including small molecules, ions, and other proteins.

LOC100653061 has been shown to play a role in a variety of physiological processes in the body, including cell signaling, inflammation, and metabolism. For example, LOC100653061 has been shown to be involved in the regulation of cell proliferation and differentiation, as well as in the development and progression of a variety of diseases, including cancer.

In addition to its role in disease, LOC100653061 has also been shown to be a potential drug target. Researchers have identified a number of small molecules that can interact with LOC100653061 and have used these compounds to study its behavior in a variety of cellular and biological systems. Some of these compounds have been shown to be able to inhibit the activity of LOC100653061, while others have been shown to enhance its activity.

The ability of LOC100653061 to be targeted by small molecules makes it an attractive candidate for drug development. However, the precise mechanism by which LOC100653061 can be inhibited or enhanced by small molecules is not well understood.

One potential mechanism by which small molecules may interact with LOC100653061 is through its role in the regulation of protein-protein interactions (PPIs). PPIs are the interactions between two or more proteins that are held together by disulfide bonds or other covalent bonds. LOC100653061 is known to be involved in the regulation of PPIs, and small molecules that can interact with it may be able to modify these interactions.

Another potential mechanism by which small molecules may interact with LOC100653061 is through its role in the regulation of cell signaling pathways. LOC100653061 has been shown to be involved in a variety of signaling pathways, including those that are involved in cell growth, differentiation, and metabolism. Small molecules that can interact with LOC100653061 may be able to regulate these pathways and have potential therapeutic applications.

In addition to its role in signaling pathways, LOC100653061 may also be involved in the regulation of inflammation. LOC100653061 has been shown to be involved in the regulation of inflammation, and small molecules that can interact with it may be able to dampen or enhance this regulation.

Overall, LOC100653061 is a protein that has a wide range of potential applications as a drug target. While more research is needed to fully understand its mechanisms of interaction with small molecules, its role in the regulation of cell signaling pathways, inflammation, and metabolism makes it an attractive candidate for further study.

Protein Name: Beta-glucuronidase-like Protein SMA4-like, Transcript Variant 1

The "LOC100653061 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100653061 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC100996385 | LOC100996412 | LOC100996583 | LOC100996637 | LOC100996643 | LOC100996664 | LOC100996770 | LOC101060017 | LOC101060106 | LOC101060179 | LOC101060400 | LOC101060445 | LOC101060524 | LOC101060632 | LOC101448202 | LOC101593348 | LOC101926887 | LOC101926948 | LOC101926953 | LOC101926959 | LOC101926969 | LOC101927002 | LOC101927020 | LOC101927025 | LOC101927026 | LOC101927040 | LOC101927053 | LOC101927060 | LOC101927066 | LOC101927082 | LOC101927108 | LOC101927143 | LOC101927164 | LOC101927166 | LOC101927169 | LOC101927179 | LOC101927188 | LOC101927199 | LOC101927216 | LOC101927243 | LOC101927245 | LOC101927253 | LOC101927263 | LOC101927269 | LOC101927314 | LOC101927369 | LOC101927394 | LOC101927421 | LOC101927476 | LOC101927483 | LOC101927495 | LOC101927518 | LOC101927531 | LOC101927548 | LOC101927550 | LOC101927571 | LOC101927588 | LOC101927598 | LOC101927605 | LOC101927609 | LOC101927627 | LOC101927636 | LOC101927668 | LOC101927712 | LOC101927727 | LOC101927741 | LOC101927745 | LOC101927770 | LOC101927787 | LOC101927825 | LOC101927827 | LOC101927834 | LOC101927840 | LOC101927853 | LOC101927855 | LOC101927857 | LOC101927863 | LOC101927896 | LOC101927897 | LOC101927910 | LOC101927932 | LOC101927942 | LOC101927947 | LOC101927960 | LOC101927967 | LOC101927971 | LOC101927995 | LOC101927998 | LOC101928004 | LOC101928007 | LOC101928008 | LOC101928012 | LOC101928014 | LOC101928047 | LOC101928053 | LOC101928080 | LOC101928093 | LOC101928120 | LOC101928135 | LOC101928143